Objective To investigate the value of Ki-67 and CyclinD1 in breast cancer in predicting and evaluating the response after neoadjuvant chemotherapy. Methods This study includes 60 patients with stage II and III breast cancer between 2019-7 and 2020-12. The response was assessed according to Miller-Payne system. The pre- and post-neoadjuvant chemotherapy Ki-67 and CyclinD1 were detected by immunohistochemistry. The changes，as well as the relationship with response，of Ki-67 and CyclinD1 were analyzed. Results The pre-neoadjuvant chemotherapy expression level of Ki-67 in the group with pathological response was significantly higher than with non pathological response(P<0.05). Ki-67 expression was decreased after neoadjuvant chemotherapy(P<0.05). The marked decrease of Ki-67 expression was significantly correlated with pathological response. There was no significant difference in the pre-neoadjuvant chemotherapy expression level of CyclinD1 between the group with pathological response and non pathological response. Also，the significant difference in the expression level of CyclinD1 between pre-neoadjuvant and post-neoadjuvant chemotherapy was not found. The pre-neoadjuvant chemotherapy expression level of CyclinD1 was significantly correlated with Ki-67. However，the pre-neoadjuvant chemotherapy expression level of CyclinD1 was significantly correlated with Ki-67.Conclusion Ki-67 in breast cancer showed value in predicting and evaluating the response after neoadjuvant chemotherapy. There was no relationship between the expression of CyclinD1 and response.